FGFR3-TACC3: A novel gene fusion in cervical cancer

Benedito A. Carneiro; Julia A. Elvin; Suneel D. Kamath; Siraj M. Ali; Ajit S. Paintal; Alvaro Restrepo; Emily Berry; Francis J. Giles; Melissa L. Johnson

doi:10.1016/j.gore.2015.06.005

FGFR3-TACC3: A novel gene fusion in cervical cancer

Benedito A. Carneiro^*, Julia A. Elvin, Suneel D. Kamath, Siraj M. Ali, Ajit S. Paintal, Alvaro Restrepo, Emily Berry, Francis J. Giles, Melissa L. Johnson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Cervical cancer epitomizes the success of cancer prevention through the human papillomavirus (HPV) vaccine, but significant challenges remain in the treatment of advanced disease. We report the first three cases of cervical carcinoma harboring an FGFR3-TACC3 fusion, which serves as a novel therapeutic target. The fusion, identified by comprehensive genomic profiling, activates the FGFR pathway that has been implicated in HPV-driven carcinogenesis. One of the patients whose tumor contained the FGFR3-TACC3 fusion was treated with an investigational FGFR tyrosine kinase inhibitor. Concomitant molecular alterations involving the PI3K/AKT/mTOR and RAF/MEK pathways were also identified and suggest other treatment strategies that deserve investigation. This case series highlights the role of comprehensive genomic profiling in the identification of new therapeutic targets and in targeted therapy selection for patients with cervical cancer.

Original language	English (US)
Pages (from-to)	53-56
Number of pages	4
Journal	Gynecologic Oncology Reports
Volume	13
DOIs	https://doi.org/10.1016/j.gore.2015.06.005
State	Published - Aug 1 2015

Keywords

Adenocarcinoma of the cervix
Cervical carcinoma
FGFR inhibitors
FGFR translocations
FGFR-TACC3
Targeted therapy

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.gore.2015.06.005

Cite this

@article{3d9fb63628c146a98b6b6df221442dc4,

title = "FGFR3-TACC3: A novel gene fusion in cervical cancer",

abstract = "Cervical cancer epitomizes the success of cancer prevention through the human papillomavirus (HPV) vaccine, but significant challenges remain in the treatment of advanced disease. We report the first three cases of cervical carcinoma harboring an FGFR3-TACC3 fusion, which serves as a novel therapeutic target. The fusion, identified by comprehensive genomic profiling, activates the FGFR pathway that has been implicated in HPV-driven carcinogenesis. One of the patients whose tumor contained the FGFR3-TACC3 fusion was treated with an investigational FGFR tyrosine kinase inhibitor. Concomitant molecular alterations involving the PI3K/AKT/mTOR and RAF/MEK pathways were also identified and suggest other treatment strategies that deserve investigation. This case series highlights the role of comprehensive genomic profiling in the identification of new therapeutic targets and in targeted therapy selection for patients with cervical cancer.",

keywords = "Adenocarcinoma of the cervix, Cervical carcinoma, FGFR inhibitors, FGFR translocations, FGFR-TACC3, Targeted therapy",

author = "Carneiro, {Benedito A.} and Elvin, {Julia A.} and Kamath, {Suneel D.} and Ali, {Siraj M.} and Paintal, {Ajit S.} and Alvaro Restrepo and Emily Berry and Giles, {Francis J.} and Johnson, {Melissa L.}",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors. Published by Elsevier Inc.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.gore.2015.06.005",

language = "English (US)",

volume = "13",

pages = "53--56",

journal = "Gynecologic Oncology Reports",

issn = "2211-338X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - FGFR3-TACC3

T2 - A novel gene fusion in cervical cancer

AU - Carneiro, Benedito A.

AU - Elvin, Julia A.

AU - Kamath, Suneel D.

AU - Ali, Siraj M.

AU - Paintal, Ajit S.

AU - Restrepo, Alvaro

AU - Berry, Emily

AU - Giles, Francis J.

AU - Johnson, Melissa L.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Cervical cancer epitomizes the success of cancer prevention through the human papillomavirus (HPV) vaccine, but significant challenges remain in the treatment of advanced disease. We report the first three cases of cervical carcinoma harboring an FGFR3-TACC3 fusion, which serves as a novel therapeutic target. The fusion, identified by comprehensive genomic profiling, activates the FGFR pathway that has been implicated in HPV-driven carcinogenesis. One of the patients whose tumor contained the FGFR3-TACC3 fusion was treated with an investigational FGFR tyrosine kinase inhibitor. Concomitant molecular alterations involving the PI3K/AKT/mTOR and RAF/MEK pathways were also identified and suggest other treatment strategies that deserve investigation. This case series highlights the role of comprehensive genomic profiling in the identification of new therapeutic targets and in targeted therapy selection for patients with cervical cancer.

AB - Cervical cancer epitomizes the success of cancer prevention through the human papillomavirus (HPV) vaccine, but significant challenges remain in the treatment of advanced disease. We report the first three cases of cervical carcinoma harboring an FGFR3-TACC3 fusion, which serves as a novel therapeutic target. The fusion, identified by comprehensive genomic profiling, activates the FGFR pathway that has been implicated in HPV-driven carcinogenesis. One of the patients whose tumor contained the FGFR3-TACC3 fusion was treated with an investigational FGFR tyrosine kinase inhibitor. Concomitant molecular alterations involving the PI3K/AKT/mTOR and RAF/MEK pathways were also identified and suggest other treatment strategies that deserve investigation. This case series highlights the role of comprehensive genomic profiling in the identification of new therapeutic targets and in targeted therapy selection for patients with cervical cancer.

KW - Adenocarcinoma of the cervix

KW - Cervical carcinoma

KW - FGFR inhibitors

KW - FGFR translocations

KW - FGFR-TACC3

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84964880964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964880964&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2015.06.005

DO - 10.1016/j.gore.2015.06.005

M3 - Article

C2 - 26425723

AN - SCOPUS:84964880964

SN - 2211-338X

VL - 13

SP - 53

EP - 56

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

ER -

FGFR3-TACC3: A novel gene fusion in cervical cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this